3,4-Dihydroxybenzylamine hydrobromide (NSC-263475 hydrobromide) inhibits DNA polymerase activity in melanoma cells and displays growth inhibitory activity in melanoma cell lines with varying degrees of tyrosinase activity.

3,4-Dihydroxybenzylamine hydrobromide (1 μM-10 mM; 48 hours) inhibits the growth of all melanoma cell lines (IC50 = 100 μM) and the SK-MELB cell line (IC50 = 122 μM). The IC50 values are 30, 84,90, and 68 μM for Human SK-MEL-30, SK-MEL-2, SK-MEL-3,RPMI-7951 cells, respectively. 3,4-Dihydroxybenzylamine hydrobromide (1 μM-10 mM; 48 hours) cytotoxicity in SK-MEL-2 and SK-MEL-28 cell lines can be enhanced by application of buthionine sulfoximine (BSO). BSO treatment sensitizes marginally pigmented cells to the effects of 3,4-DHBA, and the presence of decreses IC50 values of 3,4-DHBA by 127% in the SK-MEL-28 cell line and by 148% in the SK-MEL-2 cell line. 3,4-Dihydroxybenzylamine hydrobromide exhibits IC50values of 10, 25, 67, and 184 μM for S91A, S91B, L1210, and SCC-25 cells, respectively[1].

3,4-Dihydroxybenzylamine hydrobromide (200, 400, 600 and 800 mg/kg; i.p.; 21 days) has different effects at different doses, the median life-span are 17, 24.5, 26, 29 and 25 days respectively. 3,4-Dihydroxybenzylamine hydrobromide (1000 mg/kg; i.p.; 7 days) has the least toxic effect in non-tumor-bearing B6D2F1 mice,and mice is tolerated at this dose[2].

Cell Line: Human and Murine Melanoma Cell Lines; Non-Melanoma Cell Lines
Concentration: 1 μM-10 mM
Incubation Time: 48 hours [1]

Animal Model: C57BL/6 mice with B6D2F1 cells
Dosage: 200 mg/kg, 400 mg/kg, 600 mg/kg, and 800 mg/kg
Administration: Intraperitoneal injection [2]